Oligomers count

attyloid’s sFIDA platform technology offers a cutting-edge approach for the quantitative detection of single oligomers and aggregates, which serve as biomarkers of CNS disorders such as Alzheimer’s Disease and Parkinson’s Disease.

sFIDA technology

aggregates under the spotlight

The sFIDA platform integrates the precision of a selective immunoassay with the superior sensitivity of fluorescence microscopy to count single oligomers, aggregates, and particles. As a result, sFIDA can detect these biomarkers at unprecedented levels of sensitivity and specificity.

applications

CNS
biomarkers

  • MoA validation

  • Patient selection and stratification

  • Target engagement assaying

  • Drug efficacy testing

subvisible particle analysis

  • R&D of biologicals

  • Cell culture screening

  • Formulation development

  • QC in bioproduction

viral particle
analysis

  • Vaccine production

  • Protein expression

  • Viral therapeutics

  • Antiviral development

we are

attyloid is an academicy spin-off dedicated to the scientific rigor that the complex fields of protein misfolding and Central Nervous System (CNS) diseases demand. Our research plays a critical role in diagnosing and understanding these diseases and paving the way for innovative therapeutics.

interested in our

cutting-edge technology?

sFIDA in numbers

oligomer sizes

1.000 nm

sample volume

1.000 µl

detection limit

1.000 fM

dynamic range orders of magnitude

1

latest news

  • New Publication: Blood-Based Detection of Aβ Oligomers Reveals Impaired Clearance in Alzheimer’s Disease

    December 17, 2024

    We are proud to share that our latest study featuring attyloid’s sFIDA technology has ...

  • attyloid’s sFIDA technology unveils potential non-invasive biomarker for Alzheimer’s Disease

    November 4, 2024

    We are excited to announce a groundbreaking discovery at attyloid, made possible through our ...

  • Novel study highlights role of IAPP oligomerisation in type 2 diabetes progression

    August 23, 2024

    attyloid is thrilled to share exciting findings from a recent study that explored the ...